Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJDA1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	DEC 01	ChemPort single article sales feature unavailable
NEWS 3	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS 4	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS 5	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS 6	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS 7	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS 8	FEB 10	COMPENDEX reloaded and enhanced
NEWS 9	FEB 11	WTEXTILES reloaded and enhanced
NEWS 10	FEB 19	New patent-examiner citations in 300,000 CA/CAplus patent records provide insights into related prior art
NEWS 11	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS 12	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS 13	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS 14	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS 15	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS 16	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS 17	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats
NEWS 18	MAR 11	EPFULL backfile enhanced with additional full-text applications and grants
NEWS 19	MAR 11	ESBIOBASE reloaded and enhanced
NEWS 20	MAR 20	CAS databases on STN enhanced with new super role for nanomaterial substances
NEWS 21	MAR 23	CA/CAplus enhanced with more than 250,000 patent equivalents from China
NEWS 22	MAR 30	IMSPATENTS reloaded and enhanced
NEWS 23	APR 03	CAS coverage of exemplified prophetic substances enhanced
NEWS 24	APR 07	STN is raising the limits on saved answers

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

```
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN customer
  agreement.  This agreement limits use to scientific research.  Use
  for software development or design, implementation of commercial
  gateways, or use of CAS and STN data in the building of commercial
  products is prohibited and may result in loss of user privileges
  and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:01:30 ON 14 APR 2009

=> FIL REGISTRY
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.22       0.22

FILE 'REGISTRY' ENTERED AT 14:02:09 ON 14 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   13 APR 2009  HIGHEST RN 1134263-89-0
DICTIONARY FILE UPDATES:  13 APR 2009  HIGHEST RN 1134263-89-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> E "IMATINIB"/CN 25
E1            1     IMASORB A 700/CN
E2            1     IMASORB G 700/CN
E3            1 --> IMATINIB/CN
E4            1     IMATINIB MESILATE/CN
E5            1     IMATINIB MESYLATE/CN
E6            1     IMAVATE/CN
E7            1     IMAVEROL/CN
E8            1     IMAWOOD/CN
E9            1     IMAXILIN/CN
E10           1     IMAZABENZ/CN
E11           1     IMAZALIL/CN
E12           1     IMAZALIL HYDROCHLORIDE/CN
E13           1     IMAZALIL NITRATE/CN
E14           1     IMAZALIL PHOSPHATE/CN
E15           1     IMAZALIL SULFATE/CN
```

```
E16             1     IMAZALIL-BOSCALID MIXT./CN
E17             1     IMAZALIL-CARPROPAMID MIXT./CN
E18             1     IMAZALIL-CHLORFENAPYR MIXT./CN
E19             1     IMAZALIL-EPOXICONAZOLE MIXT./CN
E20             1     IMAZALIL-IKI 220 MIXT./CN
E21             1     IMAZALIL-PIPERONYL BUTOXIDE MIXT./CN
E22             1     IMAZALIL-TEBUCONAZOLE MIXT./CN
E23             1     IMAZALIL-THIABENDAZOLE MIXT./CN
E24             1     IMAZALIL-TOLYLFLUANID MIXT./CN
E25             1     IMAZAMETH/CN

=> S E3
L1              1 IMATINIB/CN

=> DIS L1 1 SQIDE

L1   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2009 ACS on STN
RN   152459-95-5  REGISTRY
CN   Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-
     pyridinyl)-2-pyrimidinyl]amino]phenyl]-  (CA INDEX NAME)
OTHER NAMES:
CN   4-(4-Methylpiperazin-1-ylmethyl)-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-
     2-yl]amino]phenyl]benzamide
CN   CGP 57148
CN   Imatinib
MF   C29 H31 N7 O
CI   COM
SR   CA
LC   STN Files:   ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO,
       CA, CAPLUS, CASREACT, CHEMCATS, CIN, DDFU, DRUGU, EMBASE, IMSDRUGNEWS,
       IMSPATENTS, IMSPRODUCT, IMSRESEARCH, IPA, MEDLINE, MRCK*, PATDPASPC,
       PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2,
       USPATFULL
         (*File contains numerically searchable property data)
DT.CA  CAplus document type:  Book; Conference; Dissertation; Journal; Patent;
       Preprint
RL.P   Roles from patents:  ANST (Analytical study); BIOL (Biological study);
       PREP (Preparation); PROC (Process); PRP (Properties); PRPH (Prophetic);
       RACT (Reactant or reagent); USES (Uses)
RLD.P  Roles for non-specific derivatives from patents:  ANST (Analytical
       study); BIOL (Biological study); PREP (Preparation); PRP (Properties);
       RACT (Reactant or reagent); USES (Uses)
RL.NP  Roles from non-patents:  ANST (Analytical study); BIOL (Biological
       study); FORM (Formation, nonpreparative); PREP (Preparation); PRP
       (Properties); RACT (Reactant or reagent); USES (Uses)
RLD.NP Roles for non-specific derivatives from non-patents:  ANST (Analytical
       study); BIOL (Biological study); PROC (Process); PRP (Properties); USES
       (Uses)
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

             1774 REFERENCES IN FILE CA (1907 TO DATE)
```

```
  27 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1790 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> E "IMATINIB"/CN 25
E1            1     IMASORB A 700/CN
E2            1     IMASORB G 700/CN
E3            1 --> IMATINIB/CN
E4            1     IMATINIB MESILATE/CN
E5            1     IMATINIB MESYLATE/CN
E6            1     IMAVATE/CN
E7            1     IMAVEROL/CN
E8            1     IMAWOOD/CN
E9            1     IMAXILIN/CN
E10           1     IMAZABENZ/CN
E11           1     IMAZALIL/CN
E12           1     IMAZALIL HYDROCHLORIDE/CN
E13           1     IMAZALIL NITRATE/CN
E14           1     IMAZALIL PHOSPHATE/CN
E15           1     IMAZALIL SULFATE/CN
E16           1     IMAZALIL-BOSCALID MIXT./CN
E17           1     IMAZALIL-CARPROPAMID MIXT./CN
E18           1     IMAZALIL-CHLORFENAPYR MIXT./CN
E19           1     IMAZALIL-EPOXICONAZOLE MIXT./CN
E20           1     IMAZALIL-IKI 220 MIXT./CN
E21           1     IMAZALIL-PIPERONYL BUTOXIDE MIXT./CN
E22           1     IMAZALIL-TEBUCONAZOLE MIXT./CN
E23           1     IMAZALIL-THIABENDAZOLE MIXT./CN
E24           1     IMAZALIL-TOLYLFLUANID MIXT./CN
E25           1     IMAZAMETH/CN

=> E "CHLORAMBUCIL"/CN 25
E1            1     CHLORAMBIN/CN
E2            1     CHLORAMBON/CN
E3            1 --> CHLORAMBUCIL/CN
E4            1     CHLORAMBUCIL 2-(TRIPHENYLMETHOXY)ETHYL ESTER/CN
E5            1     CHLORAMBUCIL ACID CHLORIDE/CN
E6            1     CHLORAMBUCIL HEXYL ESTER/CN
E7            1     CHLORAMBUCIL ISOPROPYL ESTER/CN
E8            1     CHLORAMBUCIL METHYL ESTER/CN
E9            1     CHLORAMBUCIL N-HYDROXYSUCCINIMIDE ESTER/CN
E10           1     CHLORAMBUCIL N-OXIDE/CN
E11           1     CHLORAMBUCIL OCTYL ESTER/CN
E12           1     CHLORAMBUCIL PHENYLETHYL ESTER/CN
E13           1     CHLORAMBUCIL PHENYLMETHYL ESTER/CN
E14           1     CHLORAMBUCIL POTASSIUM SALT/CN
E15           1     CHLORAMBUCIL PROPYL ESTER/CN
E16           1     CHLORAMBUCIL SILVER SALT/CN
E17           1     CHLORAMBUCIL SODIUM SALT/CN
E18           1     CHLORAMBUCIL TERT-BUTYL ESTER/CN
E19           1     CHLORAMBUCIL-B,B-D2/CN
E20           1     CHLORAMBUCIL-ARG-VAL-TYR-ILE-HIS-PRO-PHE/CN
E21           1     CHLORAMBUCIL-ASP-ARG-VAL-TYR-ILE-HIS-PRO-PHE/CN
E22           1     CHLORAMBUCIL-BUSULFAN MIXTURE/CN
E23           1     CHLORAMBUCIL-HIS-PRO-PHE/CN
E24           1     CHLORAMBUCIL-ILE-HIS-PRO-PHE/CN
E25           1     CHLORAMBUCIL-TETRAZOLIUM VIOLET MIXTURE/CN

=> S E3
L2            1 CHLORAMBUCIL/CN

=> DIS L2 1 SQIDE
```

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN
RN 305-03-3 REGISTRY
CN Benzenebutanoic acid, 4-[bis(2-chloroethyl)amino]- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Butyric acid, 4-[p-[bis(2-chloroethyl)amino]phenyl]- (8CI)
OTHER NAMES:
CN γ-[p-Bis(2-chloroethyl)aminophenyl]butyric acid
CN γ-[p-Di(2-chloroethyl)aminophenyl]butyric acid
CN 4-[Bis(2-chloroethyl)amino]benzenebutanoic acid
CN 4-[p-[Bis(2-chloroethyl)amino]phenyl]butyric acid
CN Ambochlorin
CN Amboclorin
CN CB 1348
CN Chlorambucil
CN Chloraminophene
CN Chlorbutin
CN Chlorobutine
CN Ecloril
CN Leukeran
CN Leukeran Tablets
CN Linfolizin
CN Linfolysin
CN Lympholysin
CN NCI 3088
CN NSC 3088
MF C14 H19 Cl2 N O2
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DRUGU, EMBASE, GMELIN*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, PHAR, PROMT, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)
DT.CA CAplus document type: Conference; Dissertation; Journal; Patent; Report
RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); PRPH (Prophetic); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)
RLD.P Roles for non-specific derivatives from patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); CMBI (Combinatorial study); FORM (Formation, nonpreparative); NANO (Nanomaterial); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)
RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)



```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

            2864 REFERENCES IN FILE CA (1907 TO DATE)
             203 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
            2869 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> d his

     (FILE 'HOME' ENTERED AT 14:01:30 ON 14 APR 2009)

     FILE 'REGISTRY' ENTERED AT 14:02:09 ON 14 APR 2009
                E "IMATINIB"/CN 25
L1             1 S E3
                E "IMATINIB"/CN 25
                E "CHLORAMBUCIL"/CN 25
L2             1 S E3

=> file medline caplus wpids uspatfull
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    15.76      15.98

FILE 'MEDLINE' ENTERED AT 14:03:11 ON 14 APR 2009

FILE 'CAPLUS' ENTERED AT 14:03:11 ON 14 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 14:03:11 ON 14 APR 2009
COPYRIGHT (C) 2009 THOMSON REUTERS

FILE 'USPATFULL' ENTERED AT 14:03:11 ON 14 APR 2009
CA INDEXING COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l1 and l2
L3          180 L1 AND L2

=> s l3 and (prd<20021112 or pd<20021112)
'20021112' NOT A VALID FIELD CODE
   1 FILES SEARCHED...
   3 FILES SEARCHED...
L4           12 L3 AND (PRD<20021112 OR PD<20021112)

=> d l4 1-12 ibib, abs, hitstr

L4   ANSWER 1 OF 12  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         2007:359020  CAPLUS
DOCUMENT NUMBER:          146:330827
TITLE:                    Bile preparations for colorectal disorders
INVENTOR(S):              Yoo, Seo Hong
PATENT ASSIGNEE(S):       USA
SOURCE:                   U.S. Pat. Appl. Publ., 24pp., Cont.-in-part of U.S.
                          Ser. No. 996,945.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   5
PATENT INFORMATION:
```

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070072828	A1	20070329	US 2006-522162	20060915 <--
US 6251428	B1	20010626	US 1999-357549	19990720 <--
US 20020031558	A1	20020314	US 2001-778154	20010205 <--
US 7303768	B2	20071204		
US 20050158408	A1	20050721	US 2004-996945	20041124 <--
AU 2004325203	A1	20060601	AU 2004-325203	20041124
CA 2588168	A1	20060601	CA 2004-2588168	20041124
EP 1819318	A1	20070822	EP 2004-812094	20041124
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 101065110	A	20071031	CN 2004-80044467	20041124
BR 2004019213	A	20071218	BR 2004-19213	20041124
JP 2008521800	T	20080626	JP 2007-543006	20041124
AU 2006203315	A1	20060824	AU 2006-203315	20060803 <--
AU 2006203315	B2	20080828		
IN 2007CN02532	A	20070907	IN 2007-CN2532	20070612
KR 2007098821	A	20071005	KR 2007-714361	20070622

PRIORITY APPLN. INFO.:	US 1998-94069P	P	19980724 <--
	US 1999-357549	A2	19990720 <--
	US 2000-180268P	P	20000204 <--
	US 2001-778154	A2	20010205 <--
	US 2004-996945	A2	20041124
	AU 2001-236685	A3	20010205 <--
	WO 2004-US39507	A	20041124

AB The present disclosure relates to methods and compns. to ameliorate or treat at least one symptom of colorectal cancer and/or adenomatous polyposis coli (APC). For example, some embodiments of the methods and compns. may reduce recurrence of colorectal adenomas and/or extend the life of a subject having colorectal cancer and/or APC. Some embodiments of the disclosure include maintaining a the total body weight in a subject having colorectal cancer and/or APC. According to some embodiments, a method of the disclosure may include administering a bile acid composition to a subject. A bile acid composition may include, in some embodiments, an aqueous solution that is free or substantially free of ppts. or particles. A aqueous solution may include (1) a bile acid, an aqueous soluble derivative of a bile acid, a bile acid salt, and/or 7-ketolithocholic acid, (2) a carbohydrate, and (3) water. An aqueous composition may further include an alkali.

IT 305-03-3, Chlorambucil 152459-95-5, Imatinib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bile prepns. for colorectal disorders)

RN 305-03-3 CAPLUS

CN Benzenebutanoic acid, 4-[bis(2-chloroethyl)amino]- (CA INDEX NAME)



RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



L4 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:1311702 CAPLUS
DOCUMENT NUMBER: 144:57525
TITLE: Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents
INVENTOR(S): Wilson, Michelle; Desai, Kishorkumar J.; Pauletti, Giovanni M.; Antoon, Mitchell K.; Clendening, Chris E.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 40 pp., Cont.-in-part of U.S. Ser. No. 126,863
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050276836	A1	20051215	US 2005-180076	20050712 <--
US 6197327	B1	20010306	US 1998-79897	19980515 <--
US 6086909	A	20000711	US 1999-249963	19990212 <--
US 6572874	B1	20030603	US 2000-626025	20000727 <--
NZ 508130	A	20020301	NZ 2000-508130	20001113 <--
AU 765269	B2	20030911	AU 2001-54192	20010703 <--
US 20030049302	A1	20030313	US 2002-226667	20020821 <--
US 6982091	B2	20060103		
US 20040005345	A1	20040108	US 2003-349029	20030122 <--
US 6905701	B2	20050614		
US 20040043071	A1	20040304	US 2003-600849	20030620 <--
US 20050249774	A1	20051110	US 2005-126863	20050510 <--

PRIORITY APPLN. INFO.:

US 1997-49325P	P	19970611 <--
US 1998-79897	A2	19980515 <--
US 1999-249963	A2	19990212 <--
US 2000-626025	A2	20000727 <--
US 2002-226667	A2	20020821 <--
US 2003-349029	A2	20030122
US 2003-600849	A2	20030620
US 2004-587454P	P	20040712
US 2005-126863	A2	20050510
AU 1998-76976	A3	19980610 <--
NZ 1998-502120	A1	19980610 <--
US 1999-146218P	P	19990728 <--
US 2001-315877P	P	20010829 <--
US 2002-390748P	P	20020621 <--

AB Disclosed is a vaginal device for delivering therapeutical and/or health-promoting agents. The vaginal device partly or completely coated by, covered by or combined with a coating or covering comprising a film, foam, strip, cap, cup or particles. The coating of the device comprises a mucoadhesive composition comprising a therapeutical and/or health-promoting agent. For example, sumatriptan vaginal suppository were prepared from Suppocire AS2X, hydroxypropyl Me cellulose as a mucoadhesive agent, and

Transcutol as a permeation enhancer.

IT 305-03-3, Chlorambucil 152459-95-5, Imatinib
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents)

RN 305-03-3 CAPLUS

CN Benzenebutanoic acid, 4-[bis(2-chloroethyl)amino]- (CA INDEX NAME)



RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



L4 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:1875 CAPLUS

DOCUMENT NUMBER: 142:92195

TITLE: Anti-IGF-I receptor antibodies, fragments and conjugates for cancer research diagnosis and therapy

INVENTOR(S): Singh, Rajeeva; Tavares, Daniel J.; Dagdigian, Nancy E.

PATENT ASSIGNEE(S): Immunogen Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 84 pp., Cont.-in-part of U.S. Ser. No. 170,390.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
US 20040265307	A1	20041230	US 2003-729441	20031208	<--
US 20030235582	A1	20031225	US 2002-170390	20020614	
CN 1678633	A	20051005	CN 2003-813742	20030612	<--
SG 141243	A1	20080428	SG 2006-2077	20030612	<--
US 20050186203	A1	20050825	US 2004-897406	20040723	<--
US 20050249728	A1	20051110	US 2004-932334	20040902	<--
AU 2004303792	A1	20050707	AU 2004-303792	20041207	
CA 2548065	A1	20050707	CA 2004-2548065	20041207	
WO 2005061541	A1	20050707	WO 2004-US38230	20041207	<--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,

NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG

EP 1692176	A1	20060823	EP 2004-811082		20041207
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU					
CN 1886424	A	20061227	CN 2004-80034889		20041207
BR 2004017406	A	20070403	BR 2004-17406		20041207
JP 2008502589	T	20080131	JP 2006-543832		20041207
MX 2006005540	A	20060817	MX 2006-5540		20060516
KR 2007001883	A	20070104	KR 2006-710010		20060523
NO 2006003155	A	20060811	NO 2006-3155		20060707
IN 2006MN00795	A	20070511	IN 2006-MN795		20060707
PRIORITY APPLN. INFO.:			US 2002-170390	A2	20020614 <--
			US 2003-729441	A1	20031208
			WO 2004-US38230	W	20041207

AB Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to, and inhibit, insulin-like growth factor-I receptor, antagonize the effects of IGF-I, IGF-II and serum on the growth and survival of tumor cells, and which are substantially devoid of agonist activity. Said antibodies and fragments thereof may be used, optionally in conjunction with other therapeutic agents, in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma, prostate cancer and pancreatic cancer, and said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of IGF-1 receptor.

IT 305-03-3D, Chlorambucil, antibody conjugates 152459-95-5D
, Imatinib, antibody conjugates
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-IGF-I receptor antibodies, fragments and conjugates for cancer research diagnosis and therapy)

RN 305-03-3 CAPLUS

CN Benzenebutanoic acid, 4-[bis(2-chloroethyl)amino]- (CA INDEX NAME)



RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



L4 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:902199 CAPLUS
DOCUMENT NUMBER: 141:374704
TITLE: Composition and uses of galectin antagonists to augment treatment of cancer or other proliferative disorders
INVENTOR(S): Chang, Yan; Sasak, Vodek
PATENT ASSIGNEE(S): Glycogenesys, Inc., USA
SOURCE: PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2004091634	A1	20041028	WO 2004-US10675	20040407	
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 20040023925	A1	20040205	US 2003-408723	20030407	<--
AU 2004229399	A1	20041028	AU 2004-229399	20040407	
CA 2521649	A1	20041028	CA 2004-2521649	20040407	
US 20040223971	A1	20041111	US 2004-819901	20040407	
EP 1617849	A1	20060125	EP 2004-759200	20040407	
EP 1617849	B1	20080618			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR					
JP 2006522163	T	20060928	JP 2006-509773	20040407	
US 20080089959	A1	20080417	US 2007-803150	20070511	

PRIORITY APPLN. INFO.:

US 2003-408723	A	20030407	
US 2003-461006P	P	20030407	
US 2003-474562P	P	20030530	
US 2001-299991P	P	20010621	<--
US 2002-176235	A2	20020620	<--
US 2004-819901	B1	20040407	
WO 2004-US10675	W	20040407	

AB The present invention is directed to methods and compns. for augmenting treatment of cancers and other proliferative disorders. In particular embodiments, the invention combines the administration of an agent that inhibits the anti-apoptotic activity of galectin-3 (e.g., a 'galectin-3 inhibitor') so as to potentiate the toxicity of a chemotherapeutic agent. In certain preferred embodiments, the conjoint therapies of the present

invention can be used to improve the efficacy of those chemotherapeutic agents whose cytotoxicity is influenced by the status of an anti-apoptotic Bcl-2 protein for the treated cell. For instance, galectin-3 inhibitors can be administered in combination with a chemotherapeutic agent that interferes with DNA replication fidelity or cell-cycle progression of cells undergoing unwanted proliferation.

IT 305-03-3, Chlorambucil 152459-95-5, Imatinib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(composition and uses of galectin antagonists to augment treatment of cancer or other proliferative disorders)

RN 305-03-3 CAPLUS
CN Benzenebutanoic acid, 4-[bis(2-chloroethyl)amino]- (CA INDEX NAME)



RN 152459-95-5 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:100803 CAPLUS
DOCUMENT NUMBER: 140:139483
TITLE: Method for enhancing the effectiveness of therapies of hyperproliferative diseases
INVENTOR(S): Chang, Yan; Sasak, Vodek
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 14 pp., Cont.-in-part of U.S. Ser. No. 176,235.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040023925	A1	20040205	US 2003-408723	20030407 <--
US 20030013681	A1	20030116	US 2002-176235	20020620 <--
US 6680306	B2	20040120		
CN 1543351	A	20041103	CN 2002-816003	20020621 <--
US 20040043962	A1	20040304	US 2003-657383	20030908 <--
AU 2004229399	A1	20041028	AU 2004-229399	20040407

CA 2521649 A1 20041028 CA 2004-2521649 20040407
WO 2004091634 A1 20041028 WO 2004-US10675 20040407
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
EP 1617849 A1 20060125 EP 2004-759200 20040407
EP 1617849 B1 20080618
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
JP 2006522163 T 20060928 JP 2006-509773 20040407
AT 398458 T 20080715 AT 2004-759200 20040407
EP 1980257 A1 20081015 EP 2008-10897 20040407
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, HR, LT, LV, MK
PRIORITY APPLN. INFO.: US 2001-299991P P 20010621 <--
US 2002-176235 A2 20020620 <--
US 2003-408723 A 20030407
US 2003-461006P P 20030407
US 2003-474562P P 20030530
EP 2004-759200 A3 20040407
WO 2004-US10675 W 20040407

AB The efficacy of conventional cancer therapies such as surgery, chemotherapy and radiation is enhanced by the use of a therapeutic material which binds to and interacts with galectins. The therapeutic material can enhance apoptosis thereby increasing the effectiveness of oncolytic agents. It can also inhibit angiogenesis thereby moderating tumor growth and/or metastasis.

IT 305-03-3, Chlorambucil 152459-95-5, Imatinib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method for enhancing effectiveness of therapies of hyperproliferative diseases)

RN 305-03-3 CAPLUS
CN Benzenebutanoic acid, 4-[bis(2-chloroethyl)amino]- (CA INDEX NAME)



RN 152459-95-5 CAPLUS
CN Benzamide, 4-[[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



L4 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:912990 CAPLUS
DOCUMENT NUMBER: 139:375014
TITLE: Methods and compositions with N-phenyl-2-pyrimidine compounds inhibiting platelet derived growth factor receptor for the treatment of graft failure
INVENTOR(S): Sukhatme, Vikas P.
PATENT ASSIGNEE(S): Beth Israel Deaconess Medical Center, USA
SOURCE: PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003094904	A1	20031120	WO 2003-US14916	20030513 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003232115	A1	20031111	AU 2003-232115	20030513 <--
CA 2490989	A1	20031120	CA 2003-2490989	20030513 <--
EP 1509219	A1	20050302	EP 2003-750120	20030513 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005533019	T	20051104	JP 2004-502990	20030513 <--
US 20050261283	A1	20051124	US 2005-514322	20050719 <--
PRIORITY APPLN. INFO.:			US 2002-380180P	P 20020513 <--
			US 2003-464023P	P 20030418
			WO 2003-US14916	W 20030513

OTHER SOURCE(S): MARPAT 139:375014

AB The present invention provides methods and compns. for treating graft failure resulting from neointimal hyperplasia. These methods and compns. feature the use of platelet derived growth factor receptor (PDGFR) inhibitor compds., such as N-phenyl-2-pyrimidine compds. (e.g., imatinib mesylate) to inhibit the biol. activity of the PDGFR and treat AV graft failure. Gleevec and rapamycin inhibited smooth muscle cell migration.

IT 152459-95-5
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(N-Ph-2-pyrimidine compds. inhibiting platelet derived growth factor receptor for treatment of graft failure)

RN 152459-95-5 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-

pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



IT 305-03-3, Chlorambucil
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(immunosuppressant, composition further containing; N-Ph-2-pyrimidine compds.
inhibiting platelet derived growth factor receptor for treatment of graft failure)
RN 305-03-3 CAPLUS
CN Benzenebutanoic acid, 4-[bis(2-chloroethyl)amino]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:892800 CAPLUS
DOCUMENT NUMBER: 139:395950
TITLE: Preparation of substituted pyrazines as protein kinase modulators
INVENTOR(S): Buhr, Chris A.; Baik, Tae-Gon; Ma, Sunghoon; Tesfai, Zerom; Wang, Longcheng; Co, Erick Wang; Epshteyn, Sergey; Kennedy, Abigail R.; Chen, Baili; Dubenko, Larisa; Anand, Neel Kumar; Tsang, Tsze H.; Nuss, John M.; Peto, Csaba J.; Rice, Kenneth D.; Ibrahim, Mohamed Abdulkader; Schnepp, Kevin Luke; Shi, Xian; Leahy, James William; Chen, Jeff; Dalrymple, Lisa Esther; Forsyth, Thimothy Patrick; Huynh, Tai Phat; Mann, Grace; Mann, Lary Wayne; Takeuchi, Craig Stacy
PATENT ASSIGNEE(S): Exelixis, Inc., USA
SOURCE: PCT Int. Appl., 468 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003093297	A2	20031113	WO 2003-US13869	20030502 <--
WO 2003093297	A3	20040701		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2484209	A1	20031113	CA 2003-2484209		20030502 <--
AU 2003234464	A1	20031117	AU 2003-234464		20030502 <--
EP 1501514	A2	20050202	EP 2003-728690		20030502 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
JP 2005530760	T	20051013	JP 2004-501436		20030502 <--
US 20060211709	A1	20060921	US 2005-513081		20050727 <--
PRIORITY APPLN. INFO.:			US 2002-377933P	P	20020503 <--
			WO 2003-US13869	W	20030502

OTHER SOURCE(S): MARPAT 139:395950
GI



I

AB This invention relates to compds. I [R1 = H, halo, CN, etc.; R2, R3 = H, alkyl, aryl, etc.; R4 = H, alkyl, aryl, etc.; Z = N, CH; A = CO, CS, C(:NR6), R7 (when A = R7, E does not exist); R6 = H, NO2, CN, etc.; R7 = (un)substituted 5-7 membered heterocyclyl; E = NR8R9, NNR2R3, OR4, etc.; R8 = H, alkyl; R9 = H, heteroarylalkyl, etc.; NR8R9 = (un)substituted 5-7 membered heteroalicyclyl; W = 6-10 membered arylene, 5-10 membered heteroarylene; X = a bond, (un)substituted alkylene, O(CH2)2-3O, etc.; Y = H, alkyl, aryl, etc.; with provisos] for modulating protein kinase enzymic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion, and to pharmaceutical compns. containing such compds. Even more specifically, the invention relates to compds. I that inhibit, regulate and/or modulate kinases, particularly Checkpoint Kinases, even more particularly Checkpoint Kinase 1, or Chk1. Preparation of representative compds. I is described. Thus, amidation of 3-amino-6-phenylpyrazinecarboxylic acid (preparation given) with benzylamine afforded 67% 3-amino-6-phenyl-N-(phenylmethyl)pyrazine-2-carboxamide which showed IC50 of 10,000 nM or greater against Chk1. Table presenting activity data with respect to Chk1 for over 1000 compds. I is given. Methods of therapeutically or prophylactically using the compds. I and compns. to treat kinase-dependent diseases and conditions are also an aspect of the invention, and include methods of treating cancer, as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, by administering effective amts. of such compds.

IT 305-03-3, Chlorambucil 152459-95-5, Imatinib
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of substituted pyrazines as protein kinase modulators for use in combination with other cancer therapeutic agents)

RN 305-03-3 CAPLUS
CN Benzenebutanoic acid, 4-[bis(2-chloroethyl)amino]- (CA INDEX NAME)



RN 152459-95-5 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



L4 ANSWER 8 OF 12 USPATFULL on STN
ACCESSION NUMBER: 2007:83360 USPATFULL
TITLE: Bile preparations for colorectal disorders
INVENTOR(S): Yoo, Seo Hong, Wyckoff, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070072828	A1	20070329
APPLICATION INFO.:	US 2006-522162	A1	20060915 (11)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-778154, filed on 5 Feb 2001, PENDING Continuation-in-part of Ser. No. US 1999-357549, filed on 20 Jul 1999, GRANTED, Pat. No. US 6251428 Continuation-in-part of Ser. No. US 2004-996945, filed on 24 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2001-778154, filed on 5 Feb 2001, PENDING Continuation-in-part of Ser. No. US 1999-357549, filed on 20 Jul 1999, GRANTED, Pat. No. US 6251428

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-180268P	20000204 (60)	<--
	US 1998-94069P	19980724 (60)	<--
	US 2000-180268P	20000204 (60)	<--
	US 1998-94069P	19980724 (60)	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BAKER BOTTS L.L.P., PATENT DEPARTMENT, 98 SAN JACINTO BLVD., SUITE 1500, AUSTIN, TX, 78701-4039, US
NUMBER OF CLAIMS: 45
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 1675
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present disclosure relates to methods and compositions to ameliorate or treat at least one symptom of colorectal cancer and/or adenomatous polyposis coli (APC). For example, some embodiments of the methods and compositions may reduce recurrence of colorectal adenomas and/or extend the life of a subject having colorectal cancer and/or APC. Some

embodiments of the disclosure include maintaining a the total body weight in a subject having colorectal cancer and/or APC. According to some embodiments, a method of the disclosure may include administering a bile acid composition to a subject. A bile acid composition may include, in some embodiments, an aqueous solution that is free or substantially free of precipitates or particles. A aqueous solution may include (1) a bile acid, an aqueous soluble derivative of a bile acid, a bile acid salt, and/or 7-ketolithocholic acid, (2) a carbohydrate, and (3) water. An aqueous composition may further include an alkali.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 305-03-3, Chlorambucil 152459-95-5, Imatinib
(bile prepns. for colorectal disorders)
RN 305-03-3 USPATFULL
CN Benzenebutanoic acid, 4-[bis(2-chloroethyl)amino]- (CA INDEX NAME)



RN 152459-95-5 USPATFULL
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



=> d l4 1-12 ibib, abs, hitstr

L4 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:359020 CAPLUS
DOCUMENT NUMBER: 146:330827
TITLE: Bile preparations for colorectal disorders
INVENTOR(S): Yoo, Seo Hong
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 24pp., Cont.-in-part of U.S. Ser. No. 996,945.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070072828	A1	20070329	US 2006-522162	20060915 <--
US 6251428	B1	20010626	US 1999-357549	19990720 <--
US 20020031558	A1	20020314	US 2001-778154	20010205 <--
US 7303768	B2	20071204		

US 20050158408	A1	20050721	US 2004-996945	20041124	<--
AU 2004325203	A1	20060601	AU 2004-325203	20041124	
CA 2588168	A1	20060601	CA 2004-2588168	20041124	
EP 1819318	A1	20070822	EP 2004-812094	20041124	
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR					
CN 101065110	A	20071031	CN 2004-80044467	20041124	
BR 2004019213	A	20071218	BR 2004-19213	20041124	
JP 2008521800	T	20080626	JP 2007-543006	20041124	
AU 2006203315	A1	20060824	AU 2006-203315	20060803	<--
AU 2006203315	B2	20080828			
IN 2007CN02532	A	20070907	IN 2007-CN2532	20070612	
KR 2007098821	A	20071005	KR 2007-714361	20070622	
PRIORITY APPLN. INFO.:			US 1998-94069P	P 19980724	<--
			US 1999-357549	A2 19990720	<--
			US 2000-180268P	P 20000204	<--
			US 2001-778154	A2 20010205	<--
			US 2004-996945	A2 20041124	
			AU 2001-236685	A3 20010205	<--
			WO 2004-US39507	A 20041124	

AB The present disclosure relates to methods and compns. to ameliorate or treat at least one symptom of colorectal cancer and/or adenomatous polyposis coli (APC). For example, some embodiments of the methods and compns. may reduce recurrence of colorectal adenomas and/or extend the life of a subject having colorectal cancer and/or APC. Some embodiments of the disclosure include maintaining a the total body weight in a subject having colorectal cancer and/or APC. According to some embodiments, a method of the disclosure may include administering a bile acid composition to a subject. A bile acid composition may include, in some embodiments, an aqueous solution that is free or substantially free of ppts. or particles. A aqueous solution may include (1) a bile acid, an aqueous soluble derivative of a bile acid, a bile acid salt, and/or 7-ketolithocholic acid, (2) a carbohydrate, and (3) water. An aqueous composition may further include an alkali.

IT 305-03-3, Chlorambucil 152459-95-5, Imatinib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bile prepns. for colorectal disorders)

RN 305-03-3 CAPLUS

CN Benzenebutanoic acid, 4-[bis(2-chloroethyl)amino]- (CA INDEX NAME)



RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



L4 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:1311702 CAPLUS
DOCUMENT NUMBER: 144:57525
TITLE: Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents
INVENTOR(S): Wilson, Michelle; Desai, Kishorkumar J.; Pauletti, Giovanni M.; Antoon, Mitchell K.; Clendening, Chris E.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 40 pp., Cont.-in-part of U.S. Ser. No. 126,863
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
US 20050276836	A1	20051215	US 2005-180076	20050712	<--
US 6197327	B1	20010306	US 1998-79897	19980515	<--
US 6086909	A	20000711	US 1999-249963	19990212	<--
US 6572874	B1	20030603	US 2000-626025	20000727	<--
NZ 508130	A	20020301	NZ 2000-508130	20001113	<--
AU 765269	B2	20030911	AU 2001-54192	20010703	<--
US 20030049302	A1	20030313	US 2002-226667	20020821	<--
US 6982091	B2	20060103			
US 20040005345	A1	20040108	US 2003-349029	20030122	<--
US 6905701	B2	20050614			
US 20040043071	A1	20040304	US 2003-600849	20030620	<--
US 20050249774	A1	20051110	US 2005-126863	20050510	<--

PRIORITY APPLN. INFO.:

US 1997-49325P	P	19970611	<--
US 1998-79897	A2	19980515	<--
US 1999-249963	A2	19990212	<--
US 2000-626025	A2	20000727	<--
US 2002-226667	A2	20020821	<--
US 2003-349029	A2	20030122	
US 2003-600849	A2	20030620	
US 2004-587454P	P	20040712	
US 2005-126863	A2	20050510	
AU 1998-76976	A3	19980610	<--
NZ 1998-502120	A1	19980610	<--
US 1999-146218P	P	19990728	<--
US 2001-315877P	P	20010829	<--
US 2002-390748P	P	20020621	<--

AB Disclosed is a vaginal device for delivering therapeutical and/or health-promoting agents. The vaginal device partly or completely coated by, covered by or combined with a coating or covering comprising a film, foam, strip, cap, cup or particles. The coating of the device comprises a mucoadhesive composition comprising a therapeutical and/or health-promoting agent. For example, sumatriptan vaginal suppository were prepared from Suppocire AS2X, hydroxypropyl Me cellulose as a mucoadhesive agent, and Transcutol as a permeation enhancer.

IT 305-03-3, Chlorambucil 152459-95-5, Imatinib
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents)

RN 305-03-3 CAPLUS
CN Benzenebutanoic acid, 4-[bis(2-chloroethyl)amino]- (CA INDEX NAME)



RN 152459-95-5 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



L4 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:1875 CAPLUS
DOCUMENT NUMBER: 142:92195
TITLE: Anti-IGF-I receptor antibodies, fragments and conjugates for cancer research diagnosis and therapy
INVENTOR(S): Singh, Rajeeva; Tavares, Daniel J.; Dagdigian, Nancy E.
PATENT ASSIGNEE(S): Immunogen Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 84 pp., Cont.-in-part of U.S. Ser. No. 170,390.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
US 20040265307	A1	20041230	US 2003-729441	20031208	<--
US 20030235582	A1	20031225	US 2002-170390	20020614	
CN 1678633	A	20051005	CN 2003-813742	20030612	<--
SG 141243	A1	20080428	SG 2006-2077	20030612	<--
US 20050186203	A1	20050825	US 2004-897406	20040723	<--
US 20050249728	A1	20051110	US 2004-932334	20040902	<--
AU 2004303792	A1	20050707	AU 2004-303792	20041207	
CA 2548065	A1	20050707	CA 2004-2548065	20041207	
WO 2005061541	A1	20050707	WO 2004-US38230	20041207	<--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
EP 1692176	A1	20060823	EP 2004-811082	20041207	

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU

CN 1886424	A	20061227	CN 2004-80034889		20041207
BR 2004017406	A	20070403	BR 2004-17406		20041207
JP 2008502589	T	20080131	JP 2006-543832		20041207
MX 2006005540	A	20060817	MX 2006-5540		20060516
KR 2007001883	A	20070104	KR 2006-710010		20060523
NO 2006003155	A	20060811	NO 2006-3155		20060707
IN 2006MN00795	A	20070511	IN 2006-MN795		20060707
PRIORITY APPLN. INFO.:			US 2002-170390	A2	20020614 <--
			US 2003-729441	A1	20031208
			WO 2004-US38230	W	20041207

AB Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to, and inhibit, insulin-like growth factor-I receptor, antagonize the effects of IGF-I, IGF-II and serum on the growth and survival of tumor cells, and which are substantially devoid of agonist activity. Said antibodies and fragments thereof may be used, optionally in conjunction with other therapeutic agents, in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma, prostate cancer and pancreatic cancer, and said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of IGF-1 receptor.

IT 305-03-3D, Chlorambucil, antibody conjugates 152459-95-5D , Imatinib, antibody conjugates
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-IGF-I receptor antibodies, fragments and conjugates for cancer research diagnosis and therapy)

RN 305-03-3 CAPLUS

CN Benzenebutanoic acid, 4-[bis(2-chloroethyl)amino]- (CA INDEX NAME)



RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



L4 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:902199 CAPLUS

DOCUMENT NUMBER: 141:374704

TITLE: Composition and uses of galectin antagonists to augment treatment of cancer or other proliferative

disorders
INVENTOR(S): Chang, Yan; Sasak, Vodek
PATENT ASSIGNEE(S): Glycogenesys, Inc., USA
SOURCE: PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004091634	A1	20041028	WO 2004-US10675	20040407
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20040023925	A1	20040205	US 2003-408723	20030407 <--
AU 2004229399	A1	20041028	AU 2004-229399	20040407
CA 2521649	A1	20041028	CA 2004-2521649	20040407
US 20040223971	A1	20041111	US 2004-819901	20040407
EP 1617849	A1	20060125	EP 2004-759200	20040407
EP 1617849	B1	20080618		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2006522163	T	20060928	JP 2006-509773	20040407
US 20080089959	A1	20080417	US 2007-803150	20070511

PRIORITY APPLN. INFO.:	US 2003-408723	A	20030407
	US 2003-461006P	P	20030407
	US 2003-474562P	P	20030530
	US 2001-299991P	P	20010621 <--
	US 2002-176235	A2	20020620 <--
	US 2004-819901	B1	20040407
	WO 2004-US10675	W	20040407

AB The present invention is directed to methods and compns. for augmenting treatment of cancers and other proliferative disorders. In particular embodiments, the invention combines the administration of an agent that inhibits the anti-apoptotic activity of galectin-3 (e.g., a 'galectin-3 inhibitor') so as to potentiate the toxicity of a chemotherapeutic agent. In certain preferred embodiments, the conjoint therapies of the present invention can be used to improve the efficacy of those chemotherapeutic agents whose cytotoxicity is influenced by the status of an anti-apoptotic Bcl-2 protein for the treated cell. For instance, galectin-3 inhibitors can be administered in combination with a chemotherapeutic agent that interferes with DNA replication fidelity or cell-cycle progression of cells undergoing unwanted proliferation.

IT 305-03-3, Chlorambucil 152459-95-5, Imatinib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(composition and uses of galectin antagonists to augment treatment of cancer or other proliferative disorders)

RN 305-03-3 CAPLUS

CN Benzenebutanoic acid, 4-[bis(2-chloroethyl)amino]- (CA INDEX NAME)



RN 152459-95-5 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:100803 CAPLUS
DOCUMENT NUMBER: 140:139483
TITLE: Method for enhancing the effectiveness of therapies of hyperproliferative diseases
INVENTOR(S): Chang, Yan; Sasak, Vodek
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 14 pp., Cont.-in-part of U.S. Ser. No. 176,235.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040023925	A1	20040205	US 2003-408723	20030407 <--
US 20030013681	A1	20030116	US 2002-176235	20020620 <--
US 6680306	B2	20040120		
CN 1543351	A	20041103	CN 2002-816003	20020621 <--
US 20040043962	A1	20040304	US 2003-657383	20030908 <--
AU 2004229399	A1	20041028	AU 2004-229399	20040407
CA 2521649	A1	20041028	CA 2004-2521649	20040407
WO 2004091634	A1	20041028	WO 2004-US10675	20040407
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1617849	A1	20060125	EP 2004-759200	20040407
EP 1617849	B1	20080618		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

JP 2006522163	T	20060928	JP 2006-509773		20040407
AT 398458	T	20080715	AT 2004-759200		20040407
EP 1980257	A1	20081015	EP 2008-10897		20040407

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, HR, LT, LV, MK

PRIORITY APPLN. INFO.:	US 2001-299991P	P	20010621 <--
	US 2002-176235	A2	20020620 <--
	US 2003-408723	A	20030407
	US 2003-461006P	P	20030407
	US 2003-474562P	P	20030530
	EP 2004-759200	A3	20040407
	WO 2004-US10675	W	20040407

AB The efficacy of conventional cancer therapies such as surgery, chemotherapy and radiation is enhanced by the use of a therapeutic material which binds to and interacts with galectins. The therapeutic material can enhance apoptosis thereby increasing the effectiveness of oncolytic agents. It can also inhibit angiogenesis thereby moderating tumor growth and/or metastasis.

IT 305-03-3, Chlorambucil 152459-95-5, Imatinib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method for enhancing effectiveness of therapies of hyperproliferative diseases)

RN 305-03-3 CAPLUS
CN Benzenebutanoic acid, 4-[bis(2-chloroethyl)amino]- (CA INDEX NAME)



RN 152459-95-5 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



L4 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER:	2003:912990 CAPLUS
DOCUMENT NUMBER:	139:375014
TITLE:	Methods and compositions with N-phenyl-2-pyrimidine compounds inhibiting platelet derived growth factor receptor for the treatment of graft failure
INVENTOR(S):	Sukhatme, Vikas P.
PATENT ASSIGNEE(S):	Beth Israel Deaconess Medical Center, USA
SOURCE:	PCT Int. Appl., 106 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003094904	A1	20031120	WO 2003-US14916	20030513 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003232115	A1	20031111	AU 2003-232115	20030513 <--
CA 2490989	A1	20031120	CA 2003-2490989	20030513 <--
EP 1509219	A1	20050302	EP 2003-750120	20030513 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005533019	T	20051104	JP 2004-502990	20030513 <--
US 20050261283	A1	20051124	US 2005-514322	20050719 <--
PRIORITY APPLN. INFO.:			US 2002-380180P	P 20020513 <--
			US 2003-464023P	P 20030418
			WO 2003-US14916	W 20030513

OTHER SOURCE(S): MARPAT 139:375014

AB The present invention provides methods and compns. for treating graft failure resulting from neointimal hyperplasia. These methods and compns. feature the use of platelet derived growth factor receptor (PDGFR) inhibitor compds., such as N-phenyl-2-pyrimidine compds. (e.g., imatinib mesylate) to inhibit the biol. activity of the PDGFR and treat AV graft failure. Gleevec and rapamycin inhibited smooth muscle cell migration.

IT 152459-95-5
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(N-Ph-2-pyrimidine compds. inhibiting platelet derived growth factor receptor for treatment of graft failure)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



IT 305-03-3, Chlorambucil
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(immunosuppressant, composition further containing; N-Ph-2-pyrimidine compds.
inhibiting platelet derived growth factor receptor for treatment of graft failure)

RN 305-03-3 CAPLUS

CN Benzenebutanoic acid, 4-[bis(2-chloroethyl)amino]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:892800 CAPLUS
DOCUMENT NUMBER: 139:395950
TITLE: Preparation of substituted pyrazines as protein kinase modulators
INVENTOR(S): Buhr, Chris A.; Baik, Tae-Gon; Ma, Sunghoon; Tesfai, Zerom; Wang, Longcheng; Co, Erick Wang; Epshteyn, Sergey; Kennedy, Abigail R.; Chen, Baili; Dubenko, Larisa; Anand, Neel Kumar; Tsang, Tsze H.; Nuss, John M.; Peto, Csaba J.; Rice, Kenneth D.; Ibrahim, Mohamed Abdulkader; Schnepp, Kevin Luke; Shi, Xian; Leahy, James William; Chen, Jeff; Dalrymple, Lisa Esther; Forsyth, Thimothy Patrick; Huynh, Tai Phat; Mann, Grace; Mann, Lary Wayne; Takeuchi, Craig Stacy
PATENT ASSIGNEE(S): Exelixis, Inc., USA
SOURCE: PCT Int. Appl., 468 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003093297	A2	20031113	WO 2003-US13869	20030502 <--
WO 2003093297	A3	20040701		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2484209	A1	20031113	CA 2003-2484209	20030502 <--
AU 2003234464	A1	20031117	AU 2003-234464	20030502 <--
EP 1501514	A2	20050202	EP 2003-728690	20030502 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005530760	T	20051013	JP 2004-501436	20030502 <--
US 20060211709	A1	20060921	US 2005-513081	20050727 <--
PRIORITY APPLN. INFO.:			US 2002-377933P P	20020503 <--
			WO 2003-US13869 W	20030502

OTHER SOURCE(S): MARPAT 139:395950
GI



I

AB This invention relates to compds. I [R1 = H, halo, CN, etc.; R2, R3 = H, alkyl, aryl, etc.; R4 = H, alkyl, aryl, etc.; Z = N, CH; A = CO, CS, C(:NR6), R7 (when A = R7, E does not exist); R6 = H, NO2, CN, etc.; R7 = (un)substituted 5-7 membered heterocyclyl; E = NR8R9, NNR2R3, OR4, etc.; R8 = H, alkyl; R9 = H, heteroarylalkyl, etc.; NR8R9 = (un)substituted 5-7 membered heteroalicyclyl; W = 6-10 membered arylene, 5-10 membered heteroarylene; X = a bond, (un)substituted alkylene, O(CH2)2-3O, etc.; Y = H, alkyl, aryl, etc.; with provisos] for modulating protein kinase enzymic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion, and to pharmaceutical compns. containing such compds. Even more specifically, the invention relates to compds. I that inhibit, regulate and/or modulate kinases, particularly Checkpoint Kinases, even more particularly Checkpoint Kinase 1, or Chk1. Preparation of representative compds. I is described. Thus, amidation of 3-amino-6-phenylpyrazinecarboxylic acid (preparation given) with benzylamine afforded 67% 3-amino-6-phenyl-N-(phenylmethyl)pyrazine-2-carboxamide which showed IC50 of 10,000 nM or greater against Chk1. Table presenting activity data with respect to Chk1 for over 1000 compds. I is given. Methods of therapeutically or prophylactically using the compds. I and compns. to treat kinase-dependent diseases and conditions are also an aspect of the invention, and include methods of treating cancer, as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, by administering effective amts. of such compds.

IT 305-03-3, Chlorambucil 152459-95-5, Imatinib
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of substituted pyrazines as protein kinase modulators for use in combination with other cancer therapeutic agents)

RN 305-03-3 CAPLUS

CN Benzenebutanoic acid, 4-[bis(2-chloroethyl)amino]- (CA INDEX NAME)



RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



L4 ANSWER 8 OF 12 USPATFULL on STN
ACCESSION NUMBER: 2007:83360 USPATFULL
TITLE: Bile preparations for colorectal disorders
INVENTOR(S): Yoo, Seo Hong, Wyckoff, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070072828	A1	20070329
APPLICATION INFO.:	US 2006-522162	A1	20060915 (11)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-778154, filed on 5 Feb 2001, PENDING Continuation-in-part of Ser. No. US 1999-357549, filed on 20 Jul 1999, GRANTED, Pat. No. US 6251428 Continuation-in-part of Ser. No. US 2004-996945, filed on 24 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2001-778154, filed on 5 Feb 2001, PENDING Continuation-in-part of Ser. No. US 1999-357549, filed on 20 Jul 1999, GRANTED, Pat. No. US 6251428

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-180268P	20000204 (60)	<--
	US 1998-94069P	19980724 (60)	<--
	US 2000-180268P	20000204 (60)	<--
	US 1998-94069P	19980724 (60)	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BAKER BOTTS L.L.P., PATENT DEPARTMENT, 98 SAN JACINTO BLVD., SUITE 1500, AUSTIN, TX, 78701-4039, US
NUMBER OF CLAIMS: 45
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 1675
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present disclosure relates to methods and compositions to ameliorate or treat at least one symptom of colorectal cancer and/or adenomatous polyposis coli (APC). For example, some embodiments of the methods and compositions may reduce recurrence of colorectal adenomas and/or extend the life of a subject having colorectal cancer and/or APC. Some embodiments of the disclosure include maintaining a the total body weight in a subject having colorectal cancer and/or APC. According to some embodiments, a method of the disclosure may include administering a bile acid composition to a subject. A bile acid composition may include, in some embodiments, an aqueous solution that is free or substantially free of precipitates or particles. A aqueous solution may include (1) a bile acid, an aqueous soluble derivative of a bile acid, a bile acid salt, and/or 7-ketolithocholic acid, (2) a carbohydrate, and (3) water. An aqueous composition may further include an alkali.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 305-03-3, Chlorambucil 152459-95-5, Imatinib
(bile prepns. for colorectal disorders)
RN 305-03-3 USPATFULL
CN Benzenebutanoic acid, 4-[bis(2-chloroethyl)amino]- (CA INDEX NAME)



RN 152459-95-5 USPATFULL
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



```
=> s l1 and "nitrogen mustard"
L5          43 L1 AND "NITROGEN MUSTARD"

=> s l5 and (prd<20021112 or pd<20021112)
'20021112' NOT A VALID FIELD CODE
   2 FILES SEARCHED...
   3 FILES SEARCHED...
L6           3 L5 AND (PRD<20021112 OR PD<20021112)

=> d l6 1-3 ibib, abs

L6   ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         2003:892800  CAPLUS
DOCUMENT NUMBER:          139:395950
TITLE:                    Preparation of substituted pyrazines as protein kinase
                          modulators
INVENTOR(S):              Buhr, Chris A.; Baik, Tae-Gon; Ma, Sunghoon; Tesfai,
                          Zerom; Wang, Longcheng; Co, Erick Wang; Epshteyn,
                          Sergey; Kennedy, Abigail R.; Chen, Baili; Dubenko,
                          Larisa; Anand, Neel Kumar; Tsang, Tsze H.; Nuss, John
                          M.; Peto, Csaba J.; Rice, Kenneth D.; Ibrahim, Mohamed
                          Abdulkader; Schnepp, Kevin Luke; Shi, Xian; Leahy,
                          James William; Chen, Jeff; Dalrymple, Lisa Esther;
                          Forsyth, Thimothy Patrick; Huynh, Tai Phat; Mann,
                          Grace; Mann, Lary Wayne; Takeuchi, Craig Stacy
PATENT ASSIGNEE(S):       Exelixis, Inc., USA
SOURCE:                   PCT Int. Appl., 468 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ------------------  ----   --------    ---------------------  --------
     WO 2003093297        A2    20031113    WO 2003-US13869        20030502 <--
     WO 2003093297        A3    20040701
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
```

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2484209	A1	20031113	CA 2003-2484209	20030502	<--
AU 2003234464	A1	20031117	AU 2003-234464	20030502	<--
EP 1501514	A2	20050202	EP 2003-728690	20030502	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
JP 2005530760	T	20051013	JP 2004-501436	20030502	<--
US 20060211709	A1	20060921	US 2005-513081	20050727	<--
PRIORITY APPLN. INFO.:			US 2002-377933P	P 20020503	<--
			WO 2003-US13869	W 20030502	

OTHER SOURCE(S): MARPAT 139:395950
GI



I

AB This invention relates to compds. I [R1 = H, halo, CN, etc.; R2, R3 = H, alkyl, aryl, etc.; R4 = H, alkyl, aryl, etc.; Z = N, CH; A = CO, CS, C(:NR6), R7 (when A = R7, E does not exist); R6 = H, NO2, CN, etc.; R7 = (un)substituted 5-7 membered heterocyclyl; E = NR8R9, NNR2R3, OR4, etc.; R8 = H, alkyl; R9 = H, heteroarylalkyl, etc.; NR8R9 = (un)substituted 5-7 membered heteroalicyclyl; W = 6-10 membered arylene, 5-10 membered heteroarylene; X = a bond, (un)substituted alkylene, O(CH2)2-3O, etc.; Y = H, alkyl, aryl, etc.; with provisos] for modulating protein kinase enzymic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion, and to pharmaceutical compns. containing such compds. Even more specifically, the invention relates to compds. I that inhibit, regulate and/or modulate kinases, particularly Checkpoint Kinases, even more particularly Checkpoint Kinase 1, or Chk1. Preparation of representative compds. I is described. Thus, amidation of 3-amino-6-phenylpyrazinecarboxylic acid (preparation given) with benzylamine afforded 67% 3-amino-6-phenyl-N-(phenylmethyl)pyrazine-2-carboxamide which showed IC50 of 10,000 nM or greater against Chk1. Table presenting activity data with respect to Chk1 for over 1000 compds. I is given. Methods of therapeutically or prophylactically using the compds. I and compns. to treat kinase-dependent diseases and conditions are also an aspect of the invention, and include methods of treating cancer, as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, by administering effective amts. of such compds.

L6 ANSWER 2 OF 3 USPATFULL on STN
ACCESSION NUMBER: 2006:248314 USPATFULL
TITLE: Protein kinase modulators and methods of use
INVENTOR(S): Buhr, Chris A., Redwood City, CA, UNITED STATES

Baik, Tae-Gon, Foster City, CA, UNITED STATES
Ma, Sunghoon, Foster City, CA, UNITED STATES
Tesfai, Zerom, San Leandro, CA, UNITED STATES
Wang, Longcheng, South San Francisco, CA, UNITED STATES
Co, Erick Wang, Redwood City, CA, UNITED STATES
Epshteyn, Sergey, Fremont, CA, UNITED STATES
Kennedy, Abigail R., San Leandro, CA, UNITED STATES
Chen, Baili, Palo Alto, CA, UNITED STATES
Dubenko, Larisa, San Francisco, CA, UNITED STATES
Anand, Neel Kumar, Burlingame, CA, UNITED STATES
Tsang, Tsze H., El Cerrito, CA, UNITED STATES
Nuss, John M., Danville, CA, UNITED STATES
Peto, Csabaj, Alameda, CA, UNITED STATES
Rice, Kenneth D., Mill Valley, CA, UNITED STATES
Ibrahim, Mohamed Abdulkader, Mountain View, CA, UNITED STATES
Shi, Xian, San Bruno, CA, UNITED STATES
Leahy, James William, San Leandro, CA, UNITED STATES
Chen, Jeff, San Francisco, CA, UNITED STATES
Dalrymple, Lisa Esther, San Francisco, CA, UNITED STATES
Forsyth, Timothy Patrick, Hayward, CA, UNITED STATES
Huynh, Tai Phat, Oakland, CA, UNITED STATES
Mann, Grace, Brisbane, CA, UNITED STATES
Mann, Larry Wayne, Redwood City, CA, UNITED STATES
Takeuchi, Craig Stacy, Burlingame, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20060211709	A1	20060921	
APPLICATION INFO.:	US 2003-513081	A1	20030502	(10)
	WO 2003-US13869		20030502	
			20050727	PCT 371 date

	NUMBER	DATE	
PRIORITY INFORMATION:	DE 2003-103	20030109	
	US 2002-377933P	20020503 (60)	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP, 300 S. WACKER DRIVE, 32ND FLOOR, CHICAGO, IL, 60606, US
NUMBER OF CLAIMS: 56
EXEMPLARY CLAIM: 1
LINE COUNT: 18707
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Substituted aryl 1,4-pyrazine derivatives and their use in treating anxiety disorders, depression and stress related disorders are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 3 OF 3 USPATFULL on STN
ACCESSION NUMBER: 2004:165980 USPATFULL
TITLE: Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
INVENTOR(S): Masferrer, Jaime, Ballwin, MO, UNITED STATES
PATENT ASSIGNEE(S): Pharmacia Corporation, St. Louis, MO, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040127470	A1	20040701
APPLICATION INFO.:	US 2003-651916	A1	20030829 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-470951, filed on 22 Dec 1999, ABANDONED

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1998-113786P	19981223 (60)	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Charles E. Dunlap, Nelson Mullins Riley & Scarborough, LLP, P.O. Box 11070, Columbia, SC, 29211-1070
NUMBER OF CLAIMS: 34
EXEMPLARY CLAIM: 1
LINE COUNT: 8937
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a novel method of preventing and/or treating neoplasia disorders in a subject that is in need of such prevention or treatment by administering to the subject at least one Cox-2 inhibitor in combination with an EGF receptor antagonist. Compositions, pharmaceutical compositions and kits are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 14:01:30 ON 14 APR 2009)

FILE 'REGISTRY' ENTERED AT 14:02:09 ON 14 APR 2009
E "IMATINIB"/CN 25
L1 1 S E3
E "IMATINIB"/CN 25
E "CHLORAMBUCIL"/CN 25
L2 1 S E3

FILE 'MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 14:03:11 ON 14 APR 2009
L3 180 S L1 AND L2
L4 12 S L3 AND (PRD<20021112 OR PD<20021112)
L5 43 S L1 AND "NITROGEN MUSTARD"
L6 3 S L5 AND (PRD<20021112 OR PD<20021112)

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	133.18	149.16

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL

	ENTRY	SESSION
CA SUBSCRIBER PRICE	-12.30	-12.30

STN INTERNATIONAL LOGOFF AT 14:08:03 ON 14 APR 2009